Literature DB >> 6531449

Nicotinic receptors in mammalian brain.

M Williams, J L Robinson.   

Abstract

Nicotine has marked effects on CNS function increasing brain excitability and spontaneous activity and also has antinociceptive actions. Agonist radioligands for the nicotinic cholinergic receptor bind with high affinity in a saturable manner. Binding is however, insensitive to the ganglionic blockers, hexamethonium and mecamylamine. This suggests that agonists and antagonists bind to different sites on the receptor or that the nicotinic receptor in brain is different from that found in peripheral tissues. The nicotinic antagonist, dihydro-beta-erythroidine binds with high affinity (Kd = 4 nM) to rat brain membranes in a stereospecific, saturable, manner with a regional distribution similar to that seen with radiolabeled acetylcholine. Binding is insensitive to hexamethonium and mecamylamine. It is concluded that the nicotinic recognition sites to which dihydro-beta-erythroidine binds are neuromuscular rather than ganglionic in nature.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6531449     DOI: 10.1016/0278-5846(84)90056-3

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

1.  Affective analgesia following muscarinic activation of the ventral tegmental area in rats.

Authors:  Robert G Kender; Steven E Harte; Elizabeth M Munn; George S Borszcz
Journal:  J Pain       Date:  2008-04-03       Impact factor: 5.820

2.  Participation of the cholinergic system in the excessive grooming behavior induced by neuropeptide (N) glutamic acid (E) isoleucine (I) amide (NEI).

Authors:  Victoria Berberian; Mónica Silvina Sanchez; María Ester Celis
Journal:  Neurochem Res       Date:  2002-12       Impact factor: 3.996

3.  The Nicotinic Cholinergic Pathway Contributes to Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity.

Authors:  Sean F Hackett; Christopher Seidel; Sheena Abraham; Rishi Chadha; Seth D Fortmann; Peter A Campochiaro; John P Cooke
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-02-01       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.